INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

You may be eligible if

• 1. Patients with a histologic diagnosis of non-HIV related B-cell NHL or Hodgkins disease are eligible.
• 2. Patients should have documented evidence of refractory or relapsed NHL or Hodgkins disease for inclusion.
• 3. Patient should have received 1 or more prior chemotherapeutic regimens for relapse, and should have completed last course of treatment at least 3 weeks prior to enrollment.
• 4. The patient must have bidimensionally measurable or evaluable disease.
• 5. Age \> 18 years.
• 6. ECOG Performance status \< 2
• 7. Informed consent.
• 8. ANC \> 1.5, platelet count \> 100K, creatinine\< 2.0, bilirubin \< 3
• 9. Female patients must have a negative pregnancy test.